June 5, 2018 / 1:04 PM / 14 days ago

AbbVie's rheumatoid arthritis drug succeeds in late-stage study

(Reuters) - Abbvie Inc said on Tuesday its experimental drug met the main goal of halting progression of moderate-to-severe rheumatoid arthritis in a late-stage trial.

A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid

The drug, upadacitinib, was tested as a monotherapy in patients who have not been treated with chemotherapy agent methotrexate.

Upadacitinib, which belongs to a class of drugs known as JAK inhibitors, also helped improve symptoms of the disease such as swollen joint counts, the company said, adding it plans to submit a U.S. marketing application in the second half of 2018.

AbbVie, whose drug Humira is the market-leading treatment for rheumatoid arthritis, is among drugmakers developing JAK inhibitors, which work by blocking inflammation-causing enzymes known as Janus kinases.

Last week, the Food and Drug Administration approved lower doses of another JAK inhibitor developer by Eli Lilly and Incyte Corp, but gave it a label that analysts said could restrict its potential for use in a larger population.

Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur and Sriraj Kalluvila

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below